Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncimmune Appoints Lung Cancer KOL As Chief Medical Officer

This article was originally published in Clinica

Executive Summary

Dr James Jett is to join Oncimmune, a company that has developed an early-stage lung cancer test, as chief medical officer on Jan 1. He is currently Professor of Medicine in the Division of Oncology at National Jewish Health in the US; he has been the principal investigator on the National Jewish Health study on Oncimmune’s blood-based autoantibody assay for early-stage lung cancer, Early CDT-Lung. In his role at the company, Jett will be responsible for overseeing all the R&D activities, as the firm continues to expand commercialization EarlyCDT-Lung. Oncimmune toldClinica earlier this year that it was ramping up US sales of the test. The firm is also developing tests for liver and ovarian cancers.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT103015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel